- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03371719
BIOMARKER-PRØVNING av APALUTAMIDE og STRÅLING for gjentakende prostatakreft
En fase II, dobbeltblindet, placebokontrollert randomisert studie av redningsstrålebehandling med eller uten forbedret antiandrogenterapi med apalutamid ved tilbakevendende prostatakreft
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent). Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer compared to radiation therapy alone.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To determine whether, in men with post-prostatectomy prostate-specific antigen (PSA) recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone.
SECONDARY OBJECTIVES:
I. To assess whether molecular stratification by the PAM50 gene expression clustering will identify subsets of prostate cancer (luminal A or basal, luminal B) which derive the greatest benefit from anti-androgen therapy.
II. To assess overall survival. III. To assess cancer-specific mortality. IV. To assess metastasis-free survival. V. To assess distant metastasis. VI. To assess local-regional progression. VII. To assess PSA nadir during first year of treatment and prior to initiation of any hormonal salvage therapy.
VIII. To assess initiation of salvage hormonal therapy. IX. To assess PSA with a non-castrate testosterone at 1 and 3 years post randomization: PSA < 0.1 ng/ml and testosterone >= 50 ng/dl.
X. To assess acute and late physician-reported morbidity (per the Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) after SRT +/- apalutamide.
XI. To assess acute and late patient-reported symptomatic adverse events morbidity (per the patient reported outcomes [PRO]-CTCAE) after SRT +/- apalutamide.
XII. To assess testosterone levels at 3, 6, 9, 12, and 36 months post randomization.
EXPLORATORY OBJECTIVE:
I. To assess the prognostic and predictive value of the genomic classifier Decipher.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo external beam radiation therapy on day 1 for 7-8 weeks. Beginning on day of radiation therapy, patients receive placebo orally (PO) once daily (QD) on days 1-30. Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients undergo external beam radiation therapy on day 1 for 7-8 weeks. Beginning on day of radiation therapy, patients receive apalutamide PO QD on days 1-30. Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years, and then yearly thereafter.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 2R9
- The Research Institute of the McGill University Health Centre (MUHC)
-
Montreal, Quebec, Canada, H1T 2M4
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
Québec, Quebec, Canada, G1R 2J6
- CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
Arizona
-
Gilbert, Arizona, Forente stater, 85297
- Arizona Center for Cancer Care - Gilbert
-
Peoria, Arizona, Forente stater, 85381
- Arizona Center for Cancer Care-Peoria
-
Scottsdale, Arizona, Forente stater, 85258
- Arizona Center for Cancer Care - Scottsdale
-
Surprise, Arizona, Forente stater, 85374
- Arizona Center for Cancer Care-Surprise
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Forente stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Greenbrae, California, Forente stater, 94904
- Marin General Hospital
-
Los Angeles, California, Forente stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forente stater, 90048
- Cedars Sinai Medical Center
-
Los Angeles, California, Forente stater, 90033
- Los Angeles General Medical Center
-
Roseville, California, Forente stater, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Sacramento, California, Forente stater, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Forente stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Truckee, California, Forente stater, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Vallejo, California, Forente stater, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- UCHealth University of Colorado Hospital
-
Colorado Springs, Colorado, Forente stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forente stater, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Forente stater, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Forente stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forente stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Glenwood Springs, Colorado, Forente stater, 81601
- Valley View Hospital Cancer Center
-
Greeley, Colorado, Forente stater, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, Forente stater, 80538
- Medical Center of the Rockies
-
-
Connecticut
-
Stamford, Connecticut, Forente stater, 06904
- Stamford Hospital/Bennett Cancer Center
-
-
Delaware
-
Newark, Delaware, Forente stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forente stater, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Forente stater, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20037
- George Washington University Medical Center
-
-
Florida
-
Altamonte Springs, Florida, Forente stater, 32701
- AdventHealth Altamonte
-
Fort Myers, Florida, Forente stater, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Kissimmee, Florida, Forente stater, 34744
- AdventHealth Kissimmee
-
Orlando, Florida, Forente stater, 32803
- AdventHealth Orlando
-
Orlando, Florida, Forente stater, 32822
- AdventHealth East Orlando
-
Weston, Florida, Forente stater, 33331
- Cleveland Clinic-Weston
-
Winter Park, Florida, Forente stater, 32792
- AdventHealth Winter Park
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forente stater, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Forente stater, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Forente stater, 30303
- Grady Health System
-
Atlanta, Georgia, Forente stater, 30342
- Northside Hospital
-
Augusta, Georgia, Forente stater, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Forente stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- University of Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rush MD Anderson Cancer Center
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Hines, Illinois, Forente stater, 60141
- Edward Hines Jr VA Hospital
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
Peoria, Illinois, Forente stater, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Forente stater, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forente stater, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
-
Indiana
-
Fort Wayne, Indiana, Forente stater, 46805
- Parkview Hospital Randallia
-
Fort Wayne, Indiana, Forente stater, 46845
- Parkview Regional Medical Center
-
Goshen, Indiana, Forente stater, 46526
- Goshen Center for Cancer Care
-
Richmond, Indiana, Forente stater, 47374
- Reid Health
-
-
Iowa
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- University of Kansas Cancer Center
-
Olathe, Kansas, Forente stater, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Forente stater, 66210
- University of Kansas Cancer Center-Overland Park
-
Salina, Kansas, Forente stater, 67401
- Salina Regional Health Center
-
Westwood, Kansas, Forente stater, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70809
- Mary Bird Perkins Cancer Center
-
Metairie, Louisiana, Forente stater, 70006
- East Jefferson General Hospital
-
Metairie, Louisiana, Forente stater, 70006
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
-
Maine
-
Bath, Maine, Forente stater, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, Forente stater, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Forente stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, Forente stater, 04412
- Lafayette Family Cancer Center-EMMC
-
Norway, Maine, Forente stater, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, Forente stater, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Forente stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forente stater, 04073
- MaineHealth Cancer Care Center of York County
-
Sanford, Maine, Forente stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Forente stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Forente stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- University of Maryland/Greenebaum Cancer Center
-
Baltimore, Maryland, Forente stater, 21229
- Saint Agnes Hospital
-
Columbia, Maryland, Forente stater, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, Forente stater, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Massachusetts
-
Burlington, Massachusetts, Forente stater, 01805
- Lahey Hospital and Medical Center
-
Lowell, Massachusetts, Forente stater, 01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Forente stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, Forente stater, 49017
- Bronson Battle Creek
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forente stater, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Forente stater, 48346
- Michigan Healthcare Professionals Clarkston
-
Clinton Township, Michigan, Forente stater, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Forente stater, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Hospital
-
East Lansing, Michigan, Forente stater, 48823
- Michigan State University
-
Farmington Hills, Michigan, Forente stater, 48334
- Michigan Healthcare Professionals Farmington
-
Grand Rapids, Michigan, Forente stater, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Forente stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Forente stater, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Forente stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Niles, Michigan, Forente stater, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Reed City, Michigan, Forente stater, 49677
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, Forente stater, 48073
- Corewell Health William Beaumont University Hospital
-
Saint Joseph, Michigan, Forente stater, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Forente stater, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Forente stater, 49684
- Munson Medical Center
-
Troy, Michigan, Forente stater, 48098
- Michigan Healthcare Professionals Troy
-
Troy, Michigan, Forente stater, 48085
- Corewell Health Beaumont Troy Hospital
-
West Bloomfield, Michigan, Forente stater, 48322
- Henry Ford West Bloomfield Hospital
-
Wyoming, Michigan, Forente stater, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Albert Lea, Minnesota, Forente stater, 56007
- Mayo Clinic Health System in Albert Lea
-
Burnsville, Minnesota, Forente stater, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy Hospital
-
Edina, Minnesota, Forente stater, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Forente stater, 55432
- Unity Hospital
-
Mankato, Minnesota, Forente stater, 56001
- Mayo Clinic Health Systems-Mankato
-
Maple Grove, Minnesota, Forente stater, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Forente stater, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Forente stater, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forente stater, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Forente stater, 55454
- Health Partners Inc
-
Minneapolis, Minnesota, Forente stater, 55417
- Minneapolis VA Medical Center
-
Monticello, Minnesota, Forente stater, 55362
- Monticello Cancer Center
-
Robbinsdale, Minnesota, Forente stater, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic in Rochester
-
Saint Cloud, Minnesota, Forente stater, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Forente stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Shakopee, Minnesota, Forente stater, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Forente stater, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Forente stater, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Forente stater, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Forente stater, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Forente stater, 55092
- Fairview Lakes Medical Center
-
-
Mississippi
-
Jackson, Mississippi, Forente stater, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Cape Girardeau, Missouri, Forente stater, 63703
- Mercy Cancer Center - Cape Girardeau
-
City of Saint Peters, Missouri, Forente stater, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Forente stater, 63141
- Siteman Cancer Center at West County Hospital
-
Jefferson City, Missouri, Forente stater, 65109
- MU Health Care Goldschmidt Cancer Center
-
Kansas City, Missouri, Forente stater, 64128
- Kansas City Veterans Affairs Medical Center
-
Kansas City, Missouri, Forente stater, 64154
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, Forente stater, 64064
- University of Kansas Cancer Center - Lee's Summit
-
Rolla, Missouri, Forente stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forente stater, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Billings, Montana, Forente stater, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forente stater, 59405
- Benefis Sletten Cancer Institute
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Forente stater, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Forente stater, 68124
- Alegent Health Bergan Mercy Medical Center
-
-
Nevada
-
Henderson, Nevada, Forente stater, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Forente stater, 89052
- OptumCare Cancer Care at Seven Hills
-
Henderson, Nevada, Forente stater, 89052
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Forente stater, 89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson, Nevada, Forente stater, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Forente stater, 89074
- Oncology Las Vegas - Henderson
-
Las Vegas, Nevada, Forente stater, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Forente stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forente stater, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Forente stater, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, Forente stater, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Forente stater, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Forente stater, 89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Forente stater, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Forente stater, 89148
- OptumCare Cancer Care at Fort Apache
-
Las Vegas, Nevada, Forente stater, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Forente stater, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Forente stater, 89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas, Nevada, Forente stater, 89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas, Nevada, Forente stater, 89121
- Cancer Therapy and Integrative Medicine
-
Las Vegas, Nevada, Forente stater, 89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas, Nevada, Forente stater, 89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Forente stater, 89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas, Nevada, Forente stater, 89128
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Forente stater, 89102
- Desert West Surgery
-
Las Vegas, Nevada, Forente stater, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Forente stater, 89169
- University Cancer Center
-
Las Vegas, Nevada, Forente stater, 89128
- Oncology Las Vegas - Tenaya
-
Pahrump, Nevada, Forente stater, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Forente stater, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Concord, New Hampshire, Forente stater, 03301
- New Hampshire Oncology Hematology PA-Concord
-
Lebanon, New Hampshire, Forente stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Manchester, New Hampshire, Forente stater, 03103
- Solinsky Center for Cancer Care
-
-
New Jersey
-
Mount Holly, New Jersey, Forente stater, 08060
- Virtua Memorial
-
New Brunswick, New Jersey, Forente stater, 08903
- Rutgers Cancer Institute of New Jersey
-
Sewell, New Jersey, Forente stater, 08080
- Sidney Kimmel Cancer Center Washington Township
-
Somerville, New Jersey, Forente stater, 08876
- Robert Wood Johnson University Hospital Somerset
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87109
- New Mexico Oncology Hematology Consultants
-
Albuquerque, New Mexico, Forente stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Brooklyn, New York, Forente stater, 11215
- New York-Presbyterian/Brooklyn Methodist Hospital
-
Canandaigua, New York, Forente stater, 14424
- Sands Cancer Center
-
Cooperstown, New York, Forente stater, 13326
- Mary Imogene Bassett Hospital
-
New York, New York, Forente stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Forente stater, 14642
- University of Rochester
-
Rochester, New York, Forente stater, 14620
- Highland Hospital
-
Rochester, New York, Forente stater, 14606
- Wilmot Cancer Institute Radiation Oncology at Greece
-
Stony Brook, New York, Forente stater, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Forente stater, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Forente stater, 10468
- James J Peters VA Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Supply, North Carolina, Forente stater, 28462
- Novant Cancer Institute Radiation Oncology - Supply
-
Wilmington, North Carolina, Forente stater, 28401
- Novant Health New Hanover Regional Medical Center
-
Wilmington, North Carolina, Forente stater, 28401
- Novant Health Cancer Institute Radiation Oncology - Wilmington
-
-
Ohio
-
Akron, Ohio, Forente stater, 44307
- Cleveland Clinic Akron General
-
Akron, Ohio, Forente stater, 44304
- Summa Health System - Akron Campus
-
Beachwood, Ohio, Forente stater, 44122
- UHHS-Chagrin Highlands Medical Center
-
Beavercreek, Ohio, Forente stater, 45431
- Indu and Raj Soin Medical Center
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Forente stater, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chardon, Ohio, Forente stater, 44024
- Geauga Hospital
-
Cincinnati, Ohio, Forente stater, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati, Ohio, Forente stater, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cleveland, Ohio, Forente stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forente stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forente stater, 43219
- The Mark H Zangmeister Center
-
Dayton, Ohio, Forente stater, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, Forente stater, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Forente stater, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Forente stater, 45415
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Forente stater, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Forente stater, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Forente stater, 45840
- Orion Cancer Care
-
Franklin, Ohio, Forente stater, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Forente stater, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Forente stater, 45331
- Wayne Hospital
-
Greenville, Ohio, Forente stater, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Forente stater, 45429
- Kettering Medical Center
-
Kettering, Ohio, Forente stater, 45409
- Greater Dayton Cancer Center
-
Kettering, Ohio, Forente stater, 45420
- First Dayton Cancer Care
-
Mansfield, Ohio, Forente stater, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mayfield Heights, Ohio, Forente stater, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Forente stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middleburg Heights, Ohio, Forente stater, 44130
- UH Seidman Cancer Center at Southwest General Hospital
-
Parma, Ohio, Forente stater, 44129
- University Hospitals Parma Medical Center
-
Ravenna, Ohio, Forente stater, 44266
- University Hospitals Portage Medical Center
-
Sandusky, Ohio, Forente stater, 44870
- North Coast Cancer Care
-
Sandusky, Ohio, Forente stater, 44870
- UH Seidman Cancer Center at Firelands Regional Medical Center
-
Springfield, Ohio, Forente stater, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Forente stater, 45504
- Springfield Regional Medical Center
-
Strongsville, Ohio, Forente stater, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Troy, Ohio, Forente stater, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Forente stater, 45373
- Dayton Physicians LLC - Troy
-
West Chester, Ohio, Forente stater, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, Forente stater, 44145
- UHHS-Westlake Medical Center
-
Wooster, Ohio, Forente stater, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forente stater, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Gresham, Oregon, Forente stater, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Forente stater, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, Forente stater, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Forente stater, 15009
- UPMC-Heritage Valley Health System Beaver
-
Bethlehem, Pennsylvania, Forente stater, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Chadds Ford, Pennsylvania, Forente stater, 19317
- Christiana Care Health System-Concord Health Center
-
Dunmore, Pennsylvania, Forente stater, 18512
- Northeast Radiation Oncology Center
-
Farrell, Pennsylvania, Forente stater, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, Forente stater, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Harrisburg, Pennsylvania, Forente stater, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Hershey, Pennsylvania, Forente stater, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Johnstown, Pennsylvania, Forente stater, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport, Pennsylvania, Forente stater, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Monroeville, Pennsylvania, Forente stater, 15146
- UPMC Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Forente stater, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Philadelphia, Pennsylvania, Forente stater, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19114
- Jefferson Torresdale Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- UPMC-Magee Womens Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- UPMC-Shadyside Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Forente stater, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Sayre, Pennsylvania, Forente stater, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
Seneca, Pennsylvania, Forente stater, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Forente stater, 15401
- UPMC Uniontown Hospital Radiation Oncology
-
Washington, Pennsylvania, Forente stater, 15301
- UPMC Washington Hospital Radiation Oncology
-
West Reading, Pennsylvania, Forente stater, 19611
- Reading Hospital
-
Willow Grove, Pennsylvania, Forente stater, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Forente stater, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forente stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenwood, South Carolina, Forente stater, 29646
- Self Regional Healthcare
-
Greer, South Carolina, Forente stater, 29650
- Prisma Health Cancer Institute - Greer
-
Hilton Head Island, South Carolina, Forente stater, 29926
- The Radiation Oncology Center-Hilton Head/Bluffton
-
Seneca, South Carolina, Forente stater, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Forente stater, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Germantown, Tennessee, Forente stater, 38138
- The West Clinic - Wolf River
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
San Antonio, Texas, Forente stater, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Forente stater, 78229
- Audie L Murphy VA Hospital
-
-
Utah
-
American Fork, Utah, Forente stater, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Forente stater, 84720
- Sandra L Maxwell Cancer Center
-
Farmington, Utah, Forente stater, 84025
- Farmington Health Center
-
Logan, Utah, Forente stater, 84321
- Logan Regional Hospital
-
Murray, Utah, Forente stater, 84107
- Intermountain Medical Center
-
Ogden, Utah, Forente stater, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Forente stater, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Forente stater, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Forente stater, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Forente stater, 84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City, Utah, Forente stater, 84143
- LDS Hospital
-
St. George, Utah, Forente stater, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Bennington, Vermont, Forente stater, 05201
- Southwestern Vermont Medical Center
-
Berlin Corners, Vermont, Forente stater, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Forente stater, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Forente stater, 05405
- University of Vermont and State Agricultural College
-
Saint Johnsbury, Vermont, Forente stater, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Portsmouth, Virginia, Forente stater, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Forente stater, 23249
- Hunter Holmes McGuire Veterans Administration Medical Center
-
-
Washington
-
Bellingham, Washington, Forente stater, 98225
- PeaceHealth Saint Joseph Medical Center
-
Vancouver, Washington, Forente stater, 98686
- Legacy Salmon Creek Hospital
-
Walla Walla, Washington, Forente stater, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Forente stater, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Grafton, Wisconsin, Forente stater, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Forente stater, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Forente stater, 53142
- Aurora Cancer Care-Kenosha South
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Menomonee Falls, Wisconsin, Forente stater, 53051
- Froedtert Menomonee Falls Hospital
-
Milwaukee, Wisconsin, Forente stater, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Forente stater, 53295
- Zablocki Veterans Administration Medical Center
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Forente stater, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Forente stater, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Forente stater, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Forente stater, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Forente stater, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
West Allis, Wisconsin, Forente stater, 53227
- Aurora West Allis Medical Center
-
West Bend, Wisconsin, Forente stater, 53095
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Pathologically (histologically) proven diagnosis of prostate adenocarcinoma; prostatectomy must have been performed within 10 years prior to Step 1 registration and any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assisted
-
Post-prostatectomy patients with a detectable serum PSA (>= 0.1, but =< 1.0 ng/mL) at study entry (within 90 days of Step 1 registration) and at least one of the following:
-
Gleason score 7-10 (International Society of Urological Pathology [ISUP] grade group 2 to 5)
-
ISUP grade group:
- Grade group 1 = Gleason score =< 6,
- Grade group 2 = Gleason score 3 + 4 = 7,
- Grade group 3 = Gleason score 4 + 3 = 7,
- Grade group 4 = Gleason score 8,
- Grade group 5 = Gleason scores 9 and 10
-
>= T3a disease
-
Persistent elevation of PSA after prostatectomy measured within 90 days after surgery (PSA never became undetectable) of > 0.04 but < 0.2 ng/mL (PSA nadir)
-
-
pN0 or pNx
-
History/physical examination within 90 days prior to Step 1 registration
-
Karnofsky performance status of 70-100 within 90 days prior to Step 1 registration
-
Surgical formalin-fixed paraffin-embedded (FFPE) specimen must be available for submission to GenomeDx for genomic analysis on Decipher GRID platform; Note: if Decipher results have already been obtained, in lieu of tissue, results must be submitted to GenomeDx for validation and for GenomeDx to provide the subtyping needed for stratification
-
Prior androgen deprivation therapy (luteinizing hormone-releasing hormone [LHRH] agonist and/or non-steroidal anti-androgen) is allowed if discontinued at least 90 days prior to Step 1 registration and given for =< 90 days duration
- For example: patients on prior LHRH analogs (post-prostatectomy), the discontinuation date should be calculated based on the expected duration of the sustained release injection, not simply the injection date of the drug; for instance, if a 22.5 mg sustained release dose of leuprolide acetate is given (3 month duration), then the expected duration of such a dose would be 90 days after the injection date; for a 7.5 mg leuprolide (1 month duration), the discontinuation date would be 30 days after the injection date
- Please note: finasteride or dutasteride must be stopped before treatment starts but prior usage will not affect eligibility
-
Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to Step 1 registration
-
Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 90 days prior to Step 1 registration
-
Serum albumin >= 3.0 g/dL within 90 days prior to Step 1 registration
-
Glomerular filtration rate (GFR) >= 35 mL/min estimated by Cockcroft-Gault or measured directly by 24 hour urine creatinine within 90 days prior to Step 1 registration
-
Serum total bilirubin =< 1.5 x upper limit of normal (ULN) (Note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject is eligible) within 90 days prior to Step 1 registration
-
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN within 90 days prior to Step 1 registration
-
Testosterone > 50 ng/dL within 90 days prior to Step 1 registration
-
Concomitant medications known to lower the seizure threshold discontinued or substituted at least 4 weeks (30 days) prior to Step 1 registration
-
The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug
-
The patient must agree not to donate sperm during the study treatment and for 3 months after receiving the last dose of study drug
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
Exclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
Definitive clinical, radiologic, or pathologic evidence of metastatic disease (M1) or lymph node involvement (N1)
-
Prior invasive malignancy (except non-melanomatous skin cancer, carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma) unless disease free for a minimum of 2 years
-
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
History of any of the following:
- Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year prior to Step 1 registration)
- History of documented inflammatory bowel disease
- Transmural myocardial infarction within the last 4 months prior to Step 1 registration
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to Step 1 registration
- History of any condition that in the opinion of the investigator, would preclude participation in this study
-
Current evidence of any of the following:
- Known gastrointestinal disorder affecting absorption of oral medications
- Active uncontrolled infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis)
- Uncontrolled hypertension
- Any current condition that in the opinion of the investigator, would preclude participation in this study
-
Prior whole gland ablative therapy (i.e. cryoablation or high intensity focused ultrasound [HIFU]) for prostate cancer is not allowed
-
HIV positive with CD4 count < 200 cells/microliter within 30 days prior to registration
-
HIV patients under treatment with highly active antiretroviral therapy (HAART) within 30 days prior to registration regardless of CD4 count; (Note: HIV testing is not required for eligibility for this protocol as it is self-reported; this exclusion criterion is necessary because the treatments involved in this protocol may be immunosuppressive and/or interact with HAART)
-
Patients must not plan to participate in any other clinical trials while receiving treatment on this study or being followed post-protocol therapy
-
PRIOR TO STEP 2 REGISTRATION:
-
For patients who have not undergone prior Decipher analysis, submission of the specimen to GenomeDx should be as soon as possible after study registration (Step 1) as these results can take up 21 days after the specimen is received at GenomeDx; Step 2 registration must occur within 6 weeks (42 days) of Step 1 registration; if Decipher results have already been obtained, in lieu of tissue, results must be submitted to GenomeDx for validation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm 1 (radiation therapy, placebo)
Patients undergo external beam radiation therapy on day 1 for 7-8 weeks. Beginning on day of radiation therapy, patients receive placebo PO QD on days 1-30. Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given PO Undergo external beam radiation therapy
Andre navn:
|
|
Eksperimentell: Arm 2 (radiation therapy, apalutamide)
Patients undergo external beam radiation therapy on day 1 for 7-8 weeks. Beginning on day of radiation therapy, patients receive apalutamide PO QD on days 1-30. Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Undergo external beam radiation therapy
Andre navn:
Given PO
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants Alive Without Biochemical Progression (Biochemical Progression-free Survival)
Tidsramme: From randomization to biochemical progression or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
Biochemical progression is defined as the first occurrence of the following:
|
From randomization to biochemical progression or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants With Undetectable PSA (< 0.1) and Non-castrate Testosterone (≥ 50 ng/dl) at One and Three Years
Tidsramme: One and three years
|
One and three years
|
|
|
Percentage of Participants Alive (Overall Survival)
Tidsramme: From randomization to death or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. |
From randomization to death or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
|
Percentage of Participants Who Have Died Due to Prostate Cancer (Cancer-specific Mortality (CSM))
Tidsramme: From the date of randomization to the date of death due to prostate cancer or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
Prostate cancer death rates were estimated using the cumulative incidence method in which death from other causes is treated as a competing risk and alive patients are censored. |
From the date of randomization to the date of death due to prostate cancer or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
|
Percentage of Participants Alive Without Distant Metastases (Metastasis-free Survival (MFS))
Tidsramme: From randomization to date of first distant metastasis or death, or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
Distant metastases are defined as clinical or radiographic appearance of disseminated disease. MFS rates are estimated using the Kaplan-Meier method, censoring participants alive without metastases at time of analysis. |
From randomization to date of first distant metastasis or death, or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
|
Percentage of Participants With Distant Metastasis
Tidsramme: From randomization to date of first distant metastasis or death, or last follow-up if alive at time of analysis. Median follow-up at time of analysis was 5.0 years. Five-year rates are presented.
|
Distant metastases are defined as clinical or radiographic appearance of disseminated disease. Distant metastasis rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive without distant metastases are censored at last known follow-up. |
From randomization to date of first distant metastasis or death, or last follow-up if alive at time of analysis. Median follow-up at time of analysis was 5.0 years. Five-year rates are presented.
|
|
Percentage of Participants Wtih Local-regional Progression
Tidsramme: From randomization to date of first local or regional recurrence or death, or last follow-up if alive at time of analysis. Median follow-up at time of analysis was 5.0 years. Five-year rates are presented.
|
Local-regional progression is defined as recurrence within the pelvis including lymph nodes below the iliac bifurcation. Local-regional progression rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive without local-regional progression are censored at last known follow-up. |
From randomization to date of first local or regional recurrence or death, or last follow-up if alive at time of analysis. Median follow-up at time of analysis was 5.0 years. Five-year rates are presented.
|
|
PSA Nadir During First Year of Treatment and Prior to Initiation of Any Hormonal Salvage Therapy
Tidsramme: First year of treatment
|
Will be compared between the two groups using a two-sample t-test. |
First year of treatment
|
|
Percentage of Participants That Started Salvage Hormonal Therapy
Tidsramme: From randomization to initiation of salvage hormonal therapy or death, whichever occurs first, or last follow-up if alive at time of analysis. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
Initiation of salvage hormone therapy (LHRH analogues or non-study anti-androgens) that occurs after completion of SRT. Salvage hormonal therapy rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive who have not started salvage hormonal therapy are censored at last known follow-up. |
From randomization to initiation of salvage hormonal therapy or death, whichever occurs first, or last follow-up if alive at time of analysis. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented.
|
|
Number of Participants With Grade 3+ Adverse Events Occurring Within 30 Days After the Completion of RT
Tidsramme: Up to 30 days after radiation therapy, which lasts approximately 7-8 weeks from treatment start.
|
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
Up to 30 days after radiation therapy, which lasts approximately 7-8 weeks from treatment start.
|
|
Number of Participants With Grade 3+ Adverse Events Occurring More Than 30 Days After the Completion of Radiation Therapy
Tidsramme: From the end of radiation therapy (approximately 7-8 weeks from treatment start) to last follow-up. Median follow-up at time of analysis among surviving patients was 5.0 years.
|
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From the end of radiation therapy (approximately 7-8 weeks from treatment start) to last follow-up. Median follow-up at time of analysis among surviving patients was 5.0 years.
|
|
Testosterone Levels
Tidsramme: 3, 6, 9, and 12 months
|
Testosterone levels will be reported at this time points. |
3, 6, 9, and 12 months
|
|
Number of Participants With Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) Severity Score ≥ 3 (or Present) Occurring Within 30 Days After the Completion of RT
Tidsramme: Up to 5 years
|
PRO-CTCAE is a patient-reported outcome (PRO) measurement system developed to evaluate symptomatic toxicity in patients on cancer clinical trials, asking the patient about experience over the last seven days. Scores may reflect worst severity of the symptom (0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very severe), frequency of the symptom (0=Never, 1=Rarely, 2=Occasionally, 3=Frequently, 4=Almost constantly), or the symptom's interference with one's "usual or daily activities" (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). The symptom row title will indicate "Severity", "Frequency", or "Interference". All scores are compared between arms; statistical analysis results are entered for p-values < 0.05. |
Up to 5 years
|
|
Number of Participants With Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) Severity Score ≥ 3 (or Present) Occurring More Thant 30 Days After the Completion of RT
Tidsramme: From the end of radiation therapy (approximately 7-8 weeks from treatment start) to two years.
|
PRO-CTCAE is a patient-reported outcome (PRO) measurement system developed to evaluate symptomatic toxicity in patients on cancer clinical trials, asking the patient about experience over the last seven days. Scores may reflect worst severity of the symptom (0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very severe), frequency of the symptom (0=Never, 1=Rarely, 2=Occasionally, 3=Frequently, 4=Almost constantly), or the symptom's interference with one's "usual or daily activities" (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). The symptom row title will indicate "Severity", "Frequency", or "Interference". All scores are compared between arms; statistical analysis results are entered for p-values < 0.05. |
From the end of radiation therapy (approximately 7-8 weeks from treatment start) to two years.
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Felix Y Feng, NRG Oncology
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29.
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr;211(4):526-532. doi: 10.1097/JU.0000000000003890. Epub 2024 Feb 29.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Prostata sykdommer
- Mannlige urogenitale sykdommer
- Prostatiske neoplasmer
- Fysiske fenomener
- Organisasjoner
- Helsevesenets økonomi og organisasjoner
- Stråling
- Kongressene som emne
- apalutamid
Andre studie-ID-numre
- NRG-GU006
- U10CA180868 (U.S. NIH-stipend/kontrakt)
- NRG-GU006 (Annen identifikator: CTEP)
- NCI-2017-01268 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- NRG-GU006 (Annen identifikator: NRG Oncology)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .